Literature DB >> 1147589

Efficacy of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide against influenza virus infections in mice.

F E Durr, H F Lindh, M Forbes.   

Abstract

1-beta-d-Ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) was effective against strains of influenza virus types A and F, whereas amantadine hydrochloride was effective only against strains of influenza virus type A. Dose-related protective effects against lethal influenza infections in mice were obtained with single oral doses of 25 to 400 mg of ribavirin per kg administered at the time of virus inoculation or up to 24 h thereafter. Therapeutic indexes (maximum tolerated dose/median effective dose) against various strains of influenza virus ranged from 5 to 35. With multiple-dose treatment initiated immediately after virus inoculation, oral doses as low as 12 to 25 mg/kg twice daily also afforded significant protection. Treatment with ribavirin inhibited the growth of influenza virus in the lungs of mice and delayed by about 24 h the attainment of maximal viral titers, which in nontreated mice were reached within 24 to 48 h. Inhibition of viral growth was correlated with a suppression of lung consolidation. Ribavirin appears to exert its protective effects against influenza infections by inhibiting virus growth, thereby preventing virus titers from reaching levels that result in massive lung tissue destruction and death of the mice.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1147589      PMCID: PMC429186          DOI: 10.1128/AAC.7.5.582

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides.

Authors:  J T Witkowski; R K Robins; R W Sidwell; L N Simon
Journal:  J Med Chem       Date:  1972-11       Impact factor: 7.446

2.  An evaluation of a new antiviral agent "virazole" against influenza virus infections.

Authors:  T Suganuma; N Ishida
Journal:  Tohoku J Exp Med       Date:  1973-08       Impact factor: 1.848

3.  Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.

Authors:  R W Sidwell; J H Huffman; G P Khare; L B Allen; J T Witkowski; R K Robins
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

4.  In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses.

Authors:  J H Huffman; R W Sidwell; G P Khare; J T Witkowski; L B Allen; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

5.  Effect of 1-beta-D-ribofuranosyl1-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on herpes and vaccinia keratitis and encephalitis in laboratory animals.

Authors:  R W Sidwell; L B Allen; G P Khare; J H Huffman; J T Witkowski; L N Simon; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

6.  Suppression by 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) of influenza virus-induced infections in mice.

Authors:  G P Khare; R W Sidwell; J T Witkowski; L N Simon; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1973-04       Impact factor: 5.191

7.  In vitro effect of virazole against influenza viruses.

Authors:  Y Togo
Journal:  Antimicrob Agents Chemother       Date:  1973-12       Impact factor: 5.191

  7 in total
  15 in total

1.  Response of influenza virus-infected mice to selected doses of ribavirin administered intraperitoneally or by aerosol.

Authors:  R F Berendt; J S Walker; J W Dominik; E L Stephen
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

2.  Double-blind evaluation of oral ribavirin (Virazole) in experimental influenza A virus infection in volunteers.

Authors:  C R Magnussen; R G Douglas; R F Betts; F K Roth; M P Meagher
Journal:  Antimicrob Agents Chemother       Date:  1977-10       Impact factor: 5.191

Review 3.  Ribavirin: a clinical overview.

Authors:  H Fernandez; G Banks; R Smith
Journal:  Eur J Epidemiol       Date:  1986-03       Impact factor: 8.082

4.  Effects of small-particle aerosols of rimantadine and ribavirin on arterial blood pH and gas tensions and lung water content of A2 influenza-infected mice.

Authors:  J B Arensman; J W Dominik; D E Hilmas
Journal:  Antimicrob Agents Chemother       Date:  1977-07       Impact factor: 5.191

5.  In vivo inhibition of respiratory syncytial virus by ribavirin.

Authors:  J F Hruska; P E Morrow; S C Suffin; R G Douglas
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

Review 6.  Ribavirin and inosiplex: a review of their present status in viral diseases.

Authors:  T W Chang; R C Heel
Journal:  Drugs       Date:  1981-08       Impact factor: 9.546

7.  Effects of ribavirin on BHK-21 cells acutely or persistently infected with mumps virus.

Authors:  J R McCammon; V W Riesser
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

8.  Therapeutic effects of ribavirin given by the intraperitoneal or aerosol route against influenza virus infections in mice.

Authors:  E L Stephen; J W Dominik; J B Moe; J S Walker
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

9.  Anti-Influenza Drug Discovery and Development: Targeting the Virus and Its Host by All Possible Means.

Authors:  Olivier Terrier; Anny Slama-Schwok
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Novel pyrazolo[3,4-d]pyrimidine nucleoside analog with broad-spectrum antiviral activity.

Authors:  D F Smee; P A McKernan; L D Nord; R C Willis; C R Petrie; T M Riley; G R Revankar; R K Robins; R A Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.